» Articles » PMID: 11376920

Effects of Cocaine Prior to and During Bupropion Maintenance in Cocaine-abusing Volunteers

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2001 May 30
PMID 11376920
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The effects of cocaine were examined prior to and during bupropion maintenance in nonopioid-dependent cocaine abusers. Prior to bupropion maintenance, subjects underwent an experimental session during which repeated cocaine doses (0, 50, 100 mg/70 kg) were administered intranasally. Then subjects were maintained on bupropion (150 and 300 mg per day) and underwent experimental sessions as before. Cocaine, regardless of bupropion, produced dose-related increases in several stimulant-like self-reports, performance and cardiovascular measures. Bupropion decreased POMS ratings of friendliness and vigor, regardless of cocaine dose. Bupropion enhanced and attenuated cocaine-induced increases in ratings on the LSD and BG subscales of the ARCI, respectively. These results suggest that bupropion does not alter the acute subjective or cardiovascular effects of cocaine in a robust manner.

Citing Articles

Potential effect of antidepressants on remission from cocaine use disorder - A nationwide matched retrospective cohort study.

Gao Z, Winhusen T, Gorenflo M, Ghitza U, Nunes E, Saxon A Drug Alcohol Depend. 2023; 251:110958.

PMID: 37703770 PMC: 10556849. DOI: 10.1016/j.drugalcdep.2023.110958.


Naltrexone-bupropion combinations do not affect cocaine self-administration in humans.

Regnier S, Stoops W, Lile J, Alcorn 3rd J, Bolin B, Reynolds A Pharmacol Biochem Behav. 2023; 224:173526.

PMID: 36805862 PMC: 10865090. DOI: 10.1016/j.pbb.2023.173526.


Effects of chronic treatment with bupropion on self-administration of nicotine + cocaine mixtures in nonhuman primates.

de Moura F, Barkin C, Blough B, Carroll F, Mello N, Kohut S Exp Clin Psychopharmacol. 2019; 28(5):517-526.

PMID: 31789555 PMC: 8601553. DOI: 10.1037/pha0000333.


Psychostimulant addiction treatment.

Phillips K, Epstein D, Preston K Neuropharmacology. 2014; 87:150-60.

PMID: 24727297 PMC: 4524548. DOI: 10.1016/j.neuropharm.2014.04.002.


Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications.

Verrico C, Haile C, Newton T, Kosten T, De La Garza 2nd R, De La Garza R Expert Opin Investig Drugs. 2013; 22(12):1549-68.

PMID: 24033127 PMC: 4422382. DOI: 10.1517/13543784.2013.836488.